Real-world clinical outcomes of cabozantinib (cabo) as a second-line (2L) treatment for advanced hepatocellular carcinoma (aHCC)

被引：0
|
作者：
Ahn, D. [1 ]
Park, N. J. [2 ]
Locker, M. C. [2 ]
Zhou, Z-Y. [3 ]
Nie, X. [3 ]
Wang, T. [3 ]
Yu, S. [2 ]
机构：
[1] Mayo Clin, Dept Med Oncol, Phoenix, AZ USA
[2] Exelixis Inc, Dept Med Affairs, Alameda, CA USA
[3] Anal Grp Inc, Dept Healthcare, Boston, MA USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2144
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1000P
引用
收藏
页码：S613 / S613
页数：1
相关论文
共 50 条
  • [1] Real-world treatment patterns and clinical outcomes in patients receiving second-line (2L) treatment for advanced or metastatic gastric cancer (GC).
    Amonkar, Mayur
    Gomez-Ulloa, David
    Kothari, Smita
    Cheung, Winson Y.
    Chau, Ian
    Zalcberg, John Raymond
    Lara, Nuria
    Falcone, Alfredo
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [2] Cabozantinib as a Second-Line Agent in Advanced Hepatocellular Carcinoma
    Kudo, Masatoshi
    LIVER CANCER, 2018, 7 (02) : 123 - 133
  • [3] A real-world study of TACE combined with regorafenib as a second-line treatment for advanced hepatocellular carcinoma
    Liu, Shaoxing
    Gao, Song
    Guo, Jianhai
    Kou, Fuxin
    Zhang, Xin
    Liu, Baojiang
    Feng, Aiwei
    Wang, Xiaodong
    Chen, Hui
    Zhu, Xu
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] Cabozantinib as a second-line treatment option in hepatocellular carcinoma
    D'Angelo, Alberto
    Sobhani, Navid
    Bagby, Stefan
    Casadei-Gardini, Andrea
    Roviello, Giandomenico
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2020, 13 (06) : 623 - 629
  • [5] Cost-Effectiveness of Cabozantinib in the Second-Line Treatment of Advanced Hepatocellular Carcinoma
    Soto-Perez-de-Celis, Enrique
    Aguiar, Pedro N., Jr.
    Cordon, Monica L.
    Chavarri-Guerra, Yanin
    Lopes, Gilberto de Lima, Jr.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2019, 17 (06): : 669 - 675
  • [6] Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison
    Santoni, Matteo
    Aurilio, Gaetano
    Massari, Francesco
    Grande, Enrique
    Matrana, Marc R.
    Rizzo, Mimma
    De Giorgi, Ugo
    Incorvaia, Lorena
    Martignetti, Angelo
    Molina-Cerrillo, Javier
    Zabalza, Ignacio Ortego
    Mollica, Veronica
    Rizzo, Alessandro
    Battelli, Nicola
    Porta, Camillo
    CLINICAL GENITOURINARY CANCER, 2022, 20 (03) : 285 - 295
  • [7] COST OF TREATMENT-RELATED ADVERSE EVENTS (TRAES) IN SECOND-LINE (2L) ADVANCED HEPATOCELLULAR CARCINOMA (AHCC): MATCH ADJUSTED INDIRECT COMPARISON (MAIC) OF NIVOLUMAB AND REGORAFENIB
    Venkatachalam, M.
    Stenehjem, D.
    Parikh, N. D.
    Singh, P.
    Marett, B.
    Sill, B.
    Wisniewski, T.
    Prakash, V
    Shukla, P.
    Korytowsky, B.
    Siddiqui, M. K.
    VALUE IN HEALTH, 2017, 20 (09) : A502 - A503
  • [8] Real-world outcomes and patient (pt) characteristics for the second-line (2L) treatment of gastric, esophageal, or gastroesophageal junction (GEJ) adenocarcinoma (EGAC).
    Barzi, Afsaneh
    Hess, Lisa M.
    Zhu, Yajun
    Liepa, Astra M.
    Fang, Yun
    Kuder, Craig Heath
    Beyre, Julie
    Chao, Joseph
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [9] Real-world treatment patterns, survival and costs in advanced hepatocellular carcinoma (aHCC) in Ontario, Canada
    Bosse, D.
    Seung, S. J.
    Saherawala, H.
    Tieu, J.
    Wang, S.
    Shephard, C.
    Kim, Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S611 - S612
  • [10] Clinical outcomes of second-line chemotherapy in patients with advanced pancreatic adenocarcinoma: a real-world study
    Liu, Yuxiao
    Guo, Xiaofan
    Xu, Peijun
    Song, Yuning
    Huang, Jing
    Chen, Xingyun
    Zhu, Wenbo
    Hao, Jihui
    Gao, Song
    CANCER BIOLOGY & MEDICINE, 2024, 21 (09) : 799 - 812
12345